These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31710632)

  • 21. Two-dimensional dose finding in discrete dose space.
    Wang K; Ivanova A
    Biometrics; 2005 Mar; 61(1):217-22. PubMed ID: 15737096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.
    Hirakawa A; Wages NA; Sato H; Matsui S
    Stat Med; 2015 Oct; 34(24):3194-213. PubMed ID: 25974405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials.
    Mu R; Xu G; Liu G; Pan H
    Contemp Clin Trials; 2021 Sep; 108():106504. PubMed ID: 34303862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential continual reassessment method for two-dimensional dose finding.
    Yuan Y; Yin G
    Stat Med; 2008 Nov; 27(27):5664-78. PubMed ID: 18618901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the coherence of model-based dose-finding designs for drug combination trials.
    Park Y; Liu S
    PLoS One; 2020; 15(11):e0242561. PubMed ID: 33253260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
    Wages NA; Fadul CE
    Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.
    Riviere MK; Yuan Y; Jourdan JH; Dubois F; Zohar S
    Stat Methods Med Res; 2018 Feb; 27(2):466-479. PubMed ID: 26988926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flexible use of copula-type model for dose-finding in drug combination clinical trials.
    Hashizume K; Tshuchida J; Sozu T
    Biometrics; 2022 Dec; 78(4):1651-1661. PubMed ID: 34181760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
    Takeda K; Taguri M; Morita S
    Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model.
    Riviere MK; Yuan Y; Dubois F; Zohar S
    Pharm Stat; 2014; 13(4):247-57. PubMed ID: 24828456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
    Li P; Liu R; Lin J; Ji Y
    J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials.
    Toumazi A; Comets E; Alberti C; Friede T; Lentz F; Stallard N; Zohar S; Ursino M
    Comput Methods Programs Biomed; 2018 Apr; 157():163-177. PubMed ID: 29477425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A surface-free design for phase I dual-agent combination trials.
    Mozgunov P; Gasparini M; Jaki T
    Stat Methods Med Res; 2020 Oct; 29(10):3093-3109. PubMed ID: 32338145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to design a dose-finding study using the continual reassessment method.
    Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
    BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian adaptive designs in single ascending dose trials in healthy volunteers.
    Guédé D; Reigner B; Vandenhende F; Derks M; Beyer U; Jordan P; Worth E; Diack C; Frey N; Peck R
    Br J Clin Pharmacol; 2014 Aug; 78(2):393-400. PubMed ID: 24528176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
    Shimamura F; Hamada C; Matsui S; Hirakawa A
    J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.